Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Phase 2

Withdrawn

Conditions: Triple Negative Breast Cancer (TNBC)

Interventions: Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Doxorubicin HCL
Drug: paclitaxel
Drug: Aldoxorubicin HCl
Drug: nab-Paclitaxel
Biological: ETBX-011
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Drug: Avelumab
Biological: ALT-803
Biological: haNK
Drug: Cyclophosphamide

First Posted Date: 2018-06-12

Last Posted Date: 2022-04-05

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03554109

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Phase 2

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: NGR-hTNF
Other: RITUXIMAB
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2018-05-24

Last Posted Date: 2022-08-03

Lead Sponsor: Andres J. M. Ferreri

Target Recruit Count: 28

Registration Number: NCT03536039

Locations: 🇮🇹
Ospedale San Raffaele, Milan, Italy

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Phase 1

Active, not recruiting

Conditions: Myeloid Diseases

Interventions: Drug: Antithymocyte globulin (Rabbit)
Drug: fludarabine
Radiation: total body irradiation
Drug: cyclophosphamide
Drug: Rituxan
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date: 2018-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03531736

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI

Completed

Conditions: Cognitive Impairment
Autoimmune Encephalitis

Interventions: Drug: rituximab
Drug: cyclophosphamide
Drug: Steroids
Drug: Intravenous immunoglobulin

First Posted Date: 2018-05-21

Last Posted Date: 2018-05-21

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 22

Registration Number: NCT03530462

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Phase 1

Withdrawn

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Hematopoietic Cell Transplantation Recipient

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Goat Milk
Other: Laboratory Biomarker Analysis
Biological: Palifermin
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2018-05-21

Last Posted Date: 2018-12-07

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT03531281

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Phase 2

Conditions: Classical Hodgkin Lymphoma
Hodgkin Disease
Hodgkin Lymphoma
Hodgkin Lymphoma (Category)

Interventions: Drug: Adriamycin
Drug: Cyclophosphamide
Drug: Vinblastine
Drug: Dacarbazine
Drug: ABVD
Drug: Brentuximab Vedotin

First Posted Date: 2018-05-17

Last Posted Date: 2019-11-18

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 220

Registration Number: NCT03527628

Locations: 🇸🇦
King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

Phase 1

Conditions: Non Hodgkin Lymphoma

Interventions: Biological: IM19
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2018-05-17

Last Posted Date: 2018-07-16

Lead Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT03528421

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Phase 2

Recruiting

Conditions: Severe Aplastic Anemia (SAA)
Hypo-Plastic Myelodysplastic Syndrome (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Drug: Cyclophosphamide
Other: Peripheral Blood Stem Cells

First Posted Date: 2018-05-11

Last Posted Date: 2024-12-19

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 56

Registration Number: NCT03520647

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative
Refractory B Acute Lymphoblastic Leukemia

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2018-05-08

Last Posted Date: 2022-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT03518112

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Phase 1

Completed

Conditions: Anatomic Stage IIIC Breast Cancer AJCC v8
Invasive Breast Carcinoma
Prognostic Stage IIB Breast Cancer AJCC v8
Breast Cancer Female
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Capecitabine
Procedure: Biospecimen Collection

First Posted Date: 2018-05-08

Last Posted Date: 2022-06-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03518242

Locations: 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇬
New Mulago Hospital, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy